Profile data is unavailable for this security.
About the company
Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
- Revenue in EUR (TTM)304.47m
- Net income in EUR40.62m
- Incorporated1997
- Employees1.11k
- LocationEckert & Ziegler SERobert-Roessle-Str.10BERLIN 13125GermanyDEU
- Phone+49 309410840
- Fax+49 30 941084112
- Websitehttps://www.ezag.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stratec SE | 256.91m | 15.65m | 248.63m | 1.42k | 15.88 | 1.04 | 7.21 | 0.9678 | 1.29 | 1.29 | 21.13 | 19.75 | 0.5825 | 1.32 | 5.65 | 177,177.20 | 3.55 | 6.72 | 4.24 | 7.96 | 29.09 | 28.41 | 6.09 | 9.63 | 1.65 | 6.85 | 0.3552 | 37.35 | -4.73 | 3.76 | 4.24 | 2.35 | -7.49 | -6.51 |
| Gerresheimer AG | 2.25bn | 23.35m | 644.86m | 13.54k | 27.62 | 0.46 | 2.31 | 0.2866 | 0.676 | 0.676 | 65.15 | 40.59 | 0.5455 | 3.73 | 7.85 | 185,328.90 | 0.6341 | 3.30 | 0.8716 | 4.68 | 26.89 | 30.04 | 1.16 | 5.84 | 0.5214 | 2.08 | 0.6022 | 41.29 | 2.28 | 7.90 | -5.52 | 6.32 | 17.58 | -49.35 |
| Paul Hartmann AG | 2.43bn | 81.51m | 810.94m | 10.09k | 9.89 | 0.6878 | 4.21 | 0.3342 | 22.95 | 22.95 | 682.93 | 330.05 | 1.16 | 1.97 | 5.54 | 240,745.70 | 4.12 | 4.21 | 5.45 | 5.79 | 59.56 | 57.30 | 3.56 | 3.35 | 1.11 | 14.11 | 0.2465 | 37.95 | 2.32 | 1.95 | 281.58 | 13.23 | 10.08 | 2.71 |
| Eckert & Ziegler SE | 304.47m | 40.62m | 940.03m | 1.11k | 22.89 | 4.00 | 16.46 | 3.09 | 0.6465 | 0.6328 | 4.85 | 3.70 | 0.6527 | 3.48 | 6.10 | 280,619.30 | 8.85 | 8.62 | 11.06 | 10.43 | 47.25 | 48.53 | 13.55 | 14.18 | 2.37 | 68.35 | 0.166 | 32.12 | 20.22 | 10.63 | 33.40 | 12.70 | 18.84 | 3.30 |
| Draegerwerk AG & Co KGaA | 3.42bn | 120.88m | 1.44bn | 16.68k | 10.70 | 0.8565 | 5.40 | 0.4226 | 6.45 | 6.45 | 182.35 | 80.56 | 1.13 | 2.51 | 5.01 | 206,009.00 | 4.00 | 3.72 | 5.94 | 5.59 | 45.35 | 44.54 | 3.53 | 3.49 | 1.03 | 7.96 | 0.1637 | 16.12 | -0.0778 | 3.92 | 12.65 | 37.91 | 0.4683 | 59.64 |
| SCHOTT Pharma AG & Co KgaA | 996.56m | 150.74m | 2.36bn | 4.81k | 15.60 | 2.53 | 9.85 | 2.36 | 1.00 | 1.00 | 6.63 | 6.18 | 0.6414 | 3.95 | 3.98 | 207,141.30 | 9.74 | 11.86 | 13.61 | 16.87 | 33.68 | 34.65 | 15.18 | 15.68 | 1.17 | -- | 0.0824 | 10.95 | 3.04 | 11.04 | -2.16 | 13.58 | 11.15 | -- |
| Carl Zeiss Meditec AG | 2.23bn | 141.22m | 2.43bn | 5.78k | 16.80 | 1.12 | -- | 1.09 | 1.61 | 1.61 | 25.45 | 24.18 | 0.6555 | 2.04 | 4.65 | 385,147.30 | 4.19 | 8.00 | 5.03 | 9.78 | 52.76 | 56.02 | 6.39 | 11.56 | 1.44 | 7.57 | 0.2165 | 33.14 | 7.82 | 10.78 | -20.99 | 2.90 | 11.23 | 1.92 |
| Ottobock SE & Co KgaA | 1.64bn | 57.90m | 3.61bn | -- | 62.33 | 15.77 | 18.95 | 2.20 | 0.9048 | 0.9048 | 25.67 | 3.58 | -- | -- | -- | -- | -- | -- | -- | -- | 52.42 | -- | 3.42 | -- | 0.6458 | 3.18 | 0.8358 | -- | 7.33 | -- | -38.37 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| JPMorgan Asset Management (UK) Ltd.as of 08 Sep 2025 | 1.90m | 3.00% |
| Norges Bank Investment Managementas of 27 Sep 2024 | 1.82m | 2.87% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 1.65m | 2.60% |
| Swedbank Robur Fonder ABas of 30 Dec 2025 | 1.08m | 1.71% |
| Janus Henderson Investors UK Ltd.as of 31 Dec 2025 | 988.16k | 1.56% |
| Groupama Asset Management SAas of 31 Jan 2025 | 914.57k | 1.44% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 758.41k | 1.19% |
| BlackRock Fund Advisorsas of 08 Jan 2026 | 737.17k | 1.16% |
| Lupus alpha Asset Management AGas of 30 Jun 2025 | 645.00k | 1.02% |
| AllianceBernstein LPas of 31 Dec 2025 | 483.95k | 0.76% |
